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INTRODUCTION: Cutaneous metastasis 
of breast cancer carries a poor prognosis, 
invokes a poor quality of life, and increases 
mortality by increasing one’s risk of bleeding 
and infection. Current therapies include 
systemic chemotherapy, surgical resection 
and radiation. These treatments are invasive 
and can have toxic side effects. 
 
CASE REPORT: A 50-year-old African-
American woman was diagnosed with left 
breast ductal carcinoma in situ (DCIS) and 
was treated with left total mastectomy. 6 
years later, she was diagnosed with stage IV 
breast adenocarcinoma (ER/PR positive and 
HER-2 negative) with recurrence and 
metastasis in multiple lymph nodes. She then 
completed chemotherapy with concurrent 
radiation therapy with good clinical and 
radiographic response. 4 years after breast 
cancer recurrence, she noted skin hardening, 
pain and hyperpigmentation over her left 
chest wall, with increasing lymphatic masses 
in her left neck and left supraclavicular area. 
PET- CT demonstrated cervical, 
supraclavicular, mediastinal and axillary 
lymphadenopathy with increased uptake in 
the left upper lung, sternum, and left chest 
wall consistent with breast cancer recurrence 
and metastasis. Despite chemotherapy, skin 
lesions continued to worsen with burning 
pain and became hard with frequent 
ulcerations. 
To treat her metastatic skin lesions to the 
upper left chest wall and left supraclavicular 
area, she was started on topical imiquimod 
5% cream to her skin lesions twice per day 
for 5 days a week. Within 4 months of 
starting topical imiquimod cream, the lesions 
decreased in size, thickness, and 
pigmentation, with resolution of ulceration as 
evidenced by serial photographic and clinical 
documentation. After improvement of skin 
lesions within 4 months of use, she started to 
use imiquimod on an as-needed basis, 
according to her symptoms and size of her 
lesions while undergoing systemic 
chemotherapy treatment. Our case 
demonstrates the longest interval between 
initial diagnosis of the patient’s primary 
breast cancer and eventual cutaneous 
metastasis (10 years) with successful 
treatment with topical imiquimod. This case 
adds to the growing body of literature 
demonstrating that topical imiquimod cream 
is a treatment option for cutaneous metastasis 
of breast cancer. Imiquimod has been 
described in recent literature to have anti-
tumor properties and ability to induce a pro-
immunogenic tumor microenvironment. The 
regression and improvement of our patient’s 
skin lesions after starting on imiquimod was 
clinically significant and further 
demonstrates the efficacy of topical 
imiquimod. It holds excellent promise as a 
treatment option for cutaneous metastasis of 
breast cancer in conjunction with systemic 
immunomodulatory therapies and 
chemotherapy for symptomatic and cosmetic 
management. 
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